抗 VEGF 药物治疗早产儿视网膜病变的研究进展

摘要

早产儿视网膜病变（ retinopathy of prematurity ，ROP）是目前全世界儿童致盲的主要原因之一[1]。以往对于阈值期和高危阈值前期的ROP采用激光或冷凝治疗，因激光和冷凝术均是破坏性的，不可避免地导致周边视野永久丧失，且并发症较多，术后仍有部分患儿病情无法控制，最终视力完全丧失。因此需要寻找新的治疗方法，近年来有较多的临床数据表明，玻璃体内注射抗血管内皮生长因子（ anti-vascular endothelial growth factor ， anti-VEGF）治疗ROP是一种有效的治疗方法。我们将对抗VEGF药物在ROP治疗的研究进展进行近期的文献综述。%Retinopathy ofprematurity ( ROP) is one of the major cause of childhood blindness worldwide.Previously, the treatment for ROP for the patients at the threshold period and before high-risk period is mainly the retinal laser and cryotherapy. However, cryotherapy and laser therapy are destructive, which can inevitably result in permanent peripheral field loss and more complications. Some patients'states of illness can't be controlled after surgery and end with total loss of vision.Hence, a new treatment method should be explored.Recently, many clinical data showed that anti -vascular endothelial growth factor therapy may be effective in treating retinopathy of prematurity. This article reviewed the recent literature on the research and progress of anti-vascular endothelial growth factor ( anti-VEGF) drugs in the treatment of retinopathy of prematurity.